Table 3.

Review of recent trials assessing SRS and immunotherapy for the treatment of melanoma brain metastases.

Author, year	# of patients	Best timing of SRS in relation to IT	Median overall survival (mo)	1- and 2-y OS	Regional brain control*
Knisley et al., 2012	27	Before	21.3	2-y 47%	Not reported
Shoukat et al., 2013	11	Not reported	28.3	Not reported	Not reported
Kiess et al., 2015	46	Concurrent, Before	12.4	1-y 65%	1-y* 31%
				Concurrent	Concurrent
				56% Before	36% Before
				40% After	8% After
Schoenfeld et al., 2015	16	Before	14.4	1-y 54%	Not reported
				2-y 25%
Patel et al., 2015	20	Within 14 d	9.1	1-y 42.9%	1-y 29.1%
				2-y 42.9%
Ahmed et al., 2016	96	Not reported	9–12**	1-y 50–66%**	1-y 21–38%**
Current study, 2016	25	Concurrent, SRS within ≤ 30 d of IT	35.8 mo	1-y OS 83%	1-y 52%
				2-y OS 64%	2-y 34.8%

^*If brain control rates were originally reported as brain recurrence rats, the recurrence rate was converted to a control rate by subtracting it from 100%. Asterisks are noted where this occurred.

^**Range reflects values for both anti-CTLA-4 and anti-PD1 agents used.